Copyright ©The Author(s) 2023.
World J Diabetes. May 15, 2023; 14(5): 549-559
Published online May 15, 2023. doi: 10.4239/wjd.v14.i5.549
Table 1 Randomized-controlled trials of glucagon-like peptide-1 receptor agonists related to fatty liver diseases
Intervention (dose)
Jendle et al[59], 2009T2DMLiraglutide (1.8-1.2-0.6 mg/day) with additional metformin administrationGlimepiride 4 mg or placebo with metformin10% attenuation ratio of liver-spleen
Fan et al[60], 2013Overweight T2DMExenatide (2 x 10µg)MetforminDecrease in liver enzyme
Shao et al[61], 2014Overweight/obese T2DMExenatide (2 x 10 µg)Insulin glargineDecrease of liver enzymes and degree of fatty liver on ultrasound
Tang et al[62], 2015Overweight/obese T2DMLiraglutide 0.6 to 1.8 mg/dayInsulin glargineNo difference in the decrease of liver fat
Armstrong et al[63], 2016Overweight/obese (17 out of 52 subjects with T2DM)Liraglutide (1.8 mg/day)PlaceboImprovement in NASH histology by 39%
Smits et al[64], 2016Overweight/obese T2DMLiraglutide (1.8 mg/day)Sitagliptin, placeboNo difference in liver fat content
Dutour et al[65], 2016T2DMExenatide 5-10 mcg twice a dayPlaceboSignificant decrease in body weight and liver fat content in the exenatide group
Khoo et al[66], 2017Obesity patients without T2DMLiraglutide (3 mg/day)Lifestyle intervention No difference in reducing liver fat
Feng et al[67], 2017T2DMLiraglutide (1.8 mg/day)Metformin or glicazideImprovement in hepatic/renal index ratio
Frøssing et al[68], 2018Women with PCOS and NAFLDLiraglutide 1.8 mg/dayPlaceboDecrease of body weight by 5.2 kg (5.6% from baseline), liver fat content by 44%, decrease the prevalence of NAFLD by about two-thirds and decrease of fasting blood glucose
Yan et al[69], 2019T2DM and NAFLDLiraglutide 1.8 mg/dayInsulin glargine and sitagliptinDecreased liver fat content, reduction of HbA1c levels in all groups, decrease in body weight
Khoo et al[70], 2019Obese and NAFLDLiraglutide 3.0 mg/dayLifestyle changingThe two groups had decrease of liver fat content
Liu et al[71], 2020T2DM and NAFLDExenatide 1.8 mg/dayInsulin glargineDecrease of liver fat content, greater reduction of visceral adipose tissue
Bizino et al[72], 2020T2DM and NAFLDLiraglutide 1.8 mg/dayPlaceboReduced body weight, but the liver content was not different
Kuchay et al[73], 2020T2DM and NAFLDDulaglutide 1.5 mg/weekPlaceboControl-corrected absolute change in liver fat content of -3.5% and relative change of -26.4%
Newsome et al[74], 2020NASH and liver fibrosisSemaglutide 0.1 mg/day, 0.2 mg/day, and 0.4 mg/dayPlaceboA higher percentage of NASH resolution without worsening of fibrosis, dose-dependent decrease of serum ALT and AST, and higher mean percentage weight loss